Investors

Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We have 16 Abbreviated New Drub Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.4 billion (IQVIA, April 2019).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

"We are forging the path to profitable growth and will continue to make the tough decisions needed to grow this business responsibly."

Damian Finio
CFO

Recent News

Teligent, Inc. Announces Third Quarter 2019 Results

BUENA, N.J. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...

Learn More

Teligent, Inc. to Hold Conference Call for Third Quarter 2019 Results on Monday November 4th, 2019

BUENA, N.J. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...

Learn More

Teligent Announces the Pricing of $34.4 Million of Series B Senior Convertible Notes

BUENA, N.J. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jers...

Learn More

Events

Investor Overview

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.